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SEXUAL DYSFUNCTION
MCID provides new perspective on erectile 
function research
Maarten Albersen and Tom F. Lue 
The erectile function domain of the International Index of Erectile Function score is a widely used patient-
reported outcome metric and a frequent clinical trial end point. Rosen and colleagues determined minimal 
clinically important difference (MCID) values for this score to overcome discrepancies between statistical 
significance and clinical significance. Before these MCIDs are implemented in the clinic, urologists should be 
aware of the advantages and limitations of this instrument.
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For a study recently published in European 
Urology, Rosen and co-workers1 tackled a 
major hurdle in optimization of the erec-
tile function (EF) domain score of the 
International Index of Erectile Function 
(IIEF) questionnaire.1 The IIEF-EF consists 
of six items pertaining to frequency, rigid-
ity, penetration ability, and maintenance of 
erection, as well as confidence in erectile 
function.2,3 Although the IIEF-EF domain 
score is widely employed as a clinical trial 
end point, there are currently no objec-
tive data on what constitutes a minimal 
clinically important difference (MCID) in 
this score. MCID was first defined as “the 
smallest difference in score in the domain 
of interest which patients perceive as bene-
ficial and which would mandate, in the 
absence of troublesome side effects and 
excessive cost, a change in the patient’s 
management.”4 Later, this definition was 
simplified to “the smallest change that is 
important to patients”, and MCID has been 
described as ‘the new metric on the block’ 
for patient-reported outcome studies.5 Thus, 
the authors set out to estimate the MCID 
for the IIEF-EF domain.
Data from 17 randomized, double-blind, 
placebo-controlled, parallel group clini-
cal trials of the phosphodiesterase type 5 
inhibitor tadalafil were pooled to generate 
a large population of patients (n = 3,345) 
treated for 12 weeks. An anchor-based 
approach was applied to determine the 
MCID for the IIEF-EF domain score5 using 
an anchor consistent with the NIH defini-
tion of erectile dysfunction (ED), which is 
“the persistent inability to attain and main-
tain an erection sufficient for satisfactory 
sexual intercourse.”6 The external anchor 
was question seven of the IIEF, “Over the 
past 4 weeks, when you attempted sexual 
intercourse how often was it satisfactory for 
you?” Minimal improvement in the anchor 
from baseline to week 12 was arbitrarily 
defined as a change from ‘little or no satis-
factory intercourse’ (score 1 or 2) to ‘satis-
factory intercourse sometimes’ (score 3). 
‘No change’ was defined as score 1 or 2 at 
baseline and score 1 or 2 at 12 weeks. Using 
these definitions, 1,240 men were identified 
with either minimal or no improvement, 
863 of whom were used for development 
of the MCIDs, followed by subsequent 
validation in the remaining 377 patients.
A receiver operating characteristic 
(ROC)-based method was used to deter-
mine the final MCID, which was found to 
be 4 points. This value discriminated well 
between mean change in IIEF-EF scores 
of the placebo and active groups in the 
develop ment sample. The estimated sensi-
tivity and specificity were 0.74 and 0.73, 
respectively. MCIDs varied significantly 
according to severity of ED at baseline but 
did not differ between age group, geographic 
region, or ED etiology.
Using MCIDs in the analysis of patient-
reported outcomes is a means of over-
coming the discrepancy between clinically 
important significance and statistical 
signifi cance. Statistically, a significant differ-
ence is one that is unlikely to be caused by 
chance and has a mathematical basis.5 In 
health-related issues, however, a difference 
might be statistically significant but of little 
importance to the health status or quality 
of life of patients. In addition, the size of a 
tested sample will often contribute to statis-
tical significance. Most multicenter clinical 
trials rely heavily on the sample size to show 
statistical signifi cance while the treatment 
effect in itself might be relatively small. This 
has been the case for several clinical trials of 
ED treatment. 
Rosen et al.1 have now identified the 
difference in IIEF-EF score that might 
actually be meaningful from the patient’s 
point of view. Any change greater than 
the MCID—in this case an increase of 4 in 
IIEF-EF score—can be considered meaning-
ful. Any patient who reaches this threshold 
can thus be considered a responder to treat-
ment. Logically, it follows that the ratio of 
responders to total patients who received a 
particular treatment indicates to a clinician 
the likelihood of their patients also respond-
ing favorably to the same treatment. This 
provides a new perspective on outcomes 
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statistical significance was accepted as 
indicative of treatment benefit, but now one 
could claim that the statistically significant 
advantage of a treatment has to at least top 
the MCID to be of benefit from the patient’s 
point of view.
However, there are some drawbacks 
to the development and use of MCIDs in 
ED research, of which clinicians should 
be aware before adopting this new metric 
in routine practice. Rosen and colleagues1 
investigated several of these limitations. 
First, different methods of determining 
MCIDs will result in different values, a 
point illustrated by the different MCIDs 
calculated using analysis of variance and 
ROC-based approaches in the discussed 
manuscript. Also, the resultant MCID will 
differ depending on the anchor. Although 
the anchor chosen by the authors was based 
on the NIH definition of ED, it might not 
be the ideal anchor for determining MCID, 
which is in essence a patient-perceived 
metric. Other anchors might be more rele-
vant and could produce different MCID 
values. Second, contradictory to the initial 
definition of MCID, cost is not taken into 
account. For example, the patient might 
report improvement, but might consider the 
benefit not worth the cost. This is particu-
larly applicable to ED research as phospho-
diesterase 5 inhibitors are not covered by 
medical insurance in many countries and 
can be costly for patients, especially those 
undergoing long-term treatment, such as 
penile rehabilitation after radical prostat-
ectomy. Third, changes are associated with 
baseline erectile function. This was beauti-
fully illustrated by Rosen and colleagues,1 
who showed that the greater the severity of 
ED before treatment, the higher the MCID. 
This association with baseline severity can 
be explained by regression to the mean, 
and both floor and ceiling effects of patient-
reported outcomes. The latter can be solved 
by proposing different MCIDs for different 
baseline scores, as illustrated in the manu-
script. Last, clinicians should be cautious of 
adopting this metric to report worsening 
of erectile function. Whether a decrease of 
4 points in the IIEF-EF domain score is indic-
ative of a clinically meaningful worsening 
of erectile function was not validated.
Rosen and colleagues1 should be con-
gratulated for taking this important leap 
in patient-reported outcome research in 
erectile function and dysfunction. The 
newly defined MCID for erectile func-
tion outcome research using the IIEF-EF 
domain helps clinicians to discern between 
statistical and clinically significant differ-
ences. The MCID further helps to counsel 
patients on potential treatment benefit. 
Researchers and clinicians, however, should 
be aware of the limitations of such an instru-
ment. Further research is needed to identify 
MCID values for other frequently employed 
patient-reported outcome measures such 
as the IIEF-5 and the sexual encounter 
profile. Furthermore, development and 
validation of an MCID for worsening of 
erectile functioning might be of benefit for 
counseling and evaluating patients with 
iatrogenic ED, which occurs following 
radical pelvic surgery and radiotherapy, or 
drug-induced ED. 
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INFECTION
Prostate biopsy—infection and 
prior fluoroquinolone exposure
Michael A. Liss
Prostate cancer screening has led to an increase in transrectal-
ultrasonography (TRUS)-guided prostate biopsies. However, clinicians 
are becoming increasingly concerned that fluoroquinolone-resistant 
organisms are the cause of infectious complications in patients who 
have undergone this procedure. Two separate studies have shown that 
patients treated with fluoroquinolone prior to transrectal biopsy are at an 
increased risk of infectious complications.
Liss, M. A. Nat. Rev. Urol. 8, 592–594 (2011); published online 11 October 2011; doi:10.1038/nrurol.2011.153
The transrectal approach for prostate biopsy 
was first described by Astraldi in 1937 
and was expanded by Hodge and associates 
to incorporate transrectal ultrasonography 
in 1989.1 Transrectal prostate biopsy is an 
outpatient procedure with a good safety 
record; therefore, an overall detection rate 
of only 30% has, thus far, been tolerated 
for this invasive diagnostic procedure.2 
However, this risk:benefit ratio changes 
as the risk of infectious complications 
increases. Such complications of prostate 
biopsy include urinary tract infection (UTI), 
epididy mitis, orchitis, prostatitis, and sep-
sis—all usually attributable to Escherichia 
coli. The current incidence of any infectious 
complication following prostate biopsy is 
about 4%, with no definitive risk increase 
with the number of biopsy cores obtained 
or with repeat biopsies.3,4 The likely mecha-
nism of infection is introduction of bacteria 
from the rectum into the bladder, prostate 
and bloodstream during the biopsy. The 
American Urological Association (AUA) 
Best Practice Policy Statement on Urologic 
Surgery Antimicrobial Prophylaxis and 
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